GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vir Biotechnology Inc (NAS:VIR) » Definitions » Owner Earnings per Share (TTM)
中文

Vir Biotechnology (Vir Biotechnology) Owner Earnings per Share (TTM) : -6.88 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Vir Biotechnology Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Vir Biotechnology's Owner Earnings per Share (TTM) ended in Dec. 2023 was $-6.88. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Vir Biotechnology's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 7 years, the highest Price-to-Owner-Earnings ratio of Vir Biotechnology was 7.10. The lowest was 2.62. And the median was 6.06.


VIR's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.115
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Vir Biotechnology's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.86. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.59. It's PE Ratio ratio for today is At Loss.

Vir Biotechnology's EPS without NRI for the three months ended in Dec. 2023 was $-0.85. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.43. It's PE Ratio without NRI ratio for today is At Loss.


Vir Biotechnology Owner Earnings per Share (TTM) Historical Data

The historical data trend for Vir Biotechnology's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vir Biotechnology Owner Earnings per Share (TTM) Chart

Vir Biotechnology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - - 8.60 -6.88

Vir Biotechnology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.60 3.84 -3.30 -5.60 -6.88

Competitive Comparison of Vir Biotechnology's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Vir Biotechnology's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vir Biotechnology's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Vir Biotechnology's Price-to-Owner-Earnings falls into.



Vir Biotechnology Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Vir Biotechnology's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -615.06
Depreciation, Depletion and Amortization 19.45
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 25.28
Change In Working Capital -304.59
Shares Outstanding (Diluted Average) 134.61

1. Start with "Net Income" from income statement. Vir Biotechnology's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-615.06 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Vir Biotechnology's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2023 was $19.45 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Vir Biotechnology's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $25.28 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Vir Biotechnology's 5-Year Average Maintenance Capital Expenditure = $25.28 Mil

5. "Change In Working Capital" is from cashflow statement. Vir Biotechnology's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 was $-304.59 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Vir Biotechnology's Shares Outstanding (Diluted Average) for the months ended in Dec. 2023 was 134.614 Mil.

Vir Biotechnology's Onwer Earnings Per Share for Dec. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -615.061 +19.451+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-25.279972376617+-304.591)/134.614
=-6.88

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=8.04/-6.88
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Vir Biotechnology Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Vir Biotechnology's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Vir Biotechnology (Vir Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
499 Illinois Street, Suite 500, San Francisco, CA, USA, 94158
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Executives
Svf Endurance (cayman) Ltd 10 percent owner C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008
Vicki L Sato director 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Phillip Pang officer: Chief Medical Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Steven J. Rice officer: Chief Administrative Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Backer Marianne De officer: Chief Executive Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Ann M. Hanly officer: Chief Technology Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Sung Lee officer: Chief Financial Officer 7000 MARINA BLVD, BRISBANE CA 94005
Johanna Friedl-naderer officer: Chief Business Officer, Global C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
George A Scangos director, officer: President and CEO C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Howard Horn officer: CFO C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Charles Elliott Sigal director 32 BREARLY ROAD, PRINCETON NJ 08540
Herbert Virgin officer: EVP, Research & CSO C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Janet Napolitano director C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Robert J More director 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001

Vir Biotechnology (Vir Biotechnology) Headlines

From GuruFocus